Cannabinoid Investigations Entering The Mainstream

With the passage last year of Proposition 215 in California and similar measures in Arizona and other states, voters have indicated their belief that marijuana should be made available for medicinal purposes. In response, the Office of National Drug Control Policy requested that the Institute of Medicine of the National Academy of Sciences undertake an 18-month study to assess the science base, the therapeutic use, and the economics of medical marijuana. The study will not be completed until th

Written byRobert Finn
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

With the passage last year of Proposition 215 in California and similar measures in Arizona and other states, voters have indicated their belief that marijuana should be made available for medicinal purposes. In response, the Office of National Drug Control Policy requested that the Institute of Medicine of the National Academy of Sciences undertake an 18-month study to assess the science base, the therapeutic use, and the economics of medical marijuana. The study will not be completed until the end of this year, but it is certain to highlight the extent to which research on medical marijuana has entered the mainstream of science.

NEW TOOLS: Wake Forest's Steven Childers notes that researchers only recently became able to study the interaction of cannabinoid compounds with their receptors. But it's not just the impetus of political events that is driving the renewed interest in studying marijuana and its active compounds, the cannabinoids. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies